SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-120000
Filing Date
2023-04-27
Accepted
2023-04-27 07:02:01
Documents
15
Period of Report
2023-04-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d467609d8k.htm   iXBRL 8-K 28493
2 EX-1.1 d467609dex11.htm EX-1.1 28479
3 EX-5.1 d467609dex51.htm EX-5.1 5865
7 GRAPHIC g467609g0426225033661.jpg GRAPHIC 2495
  Complete submission text file 0001193125-23-120000.txt   199491

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA abos-20230427.xsd EX-101.SCH 2863
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE abos-20230427_lab.xml EX-101.LAB 17979
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abos-20230427_pre.xml EX-101.PRE 11267
9 EXTRACTED XBRL INSTANCE DOCUMENT d467609d8k_htm.xml XML 3341
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 23851811
SIC: 2836 Biological Products, (No Diagnostic Substances)